Cryotherapy for Human Papillomavirus Clearance in Biopsy-confirmed Cervical Low-grade Squamous Intraepithelial Lesions (Cryotherapy)

This will be a hospital-based, parallel, assessor-blinded, randomized controlled trial. Study subjects refer to LSIL patients, more than 30 years-old, with positive HPV testing who do not have any contraindication of performing cryotherapy. Therefore, after recruitment LSIL patients whose age more than 30 years-old, we will exclude only those who have negative HPV testing or any contraindications of performing cryotherapy. The primary outcome is HPV clearance (negative HPV testing for the baseline HPV type) at 12 months after the treatment. Subjects will be randomly allocated to be treated by cryotherapy or observation only by using block randomization with varied block size of 2, 4, and 6. The sample size of at least 25 for each arm was planned to have the power of 80% to detect 20% difference rates of HPV clearance after 12 months of treatment between the two arms, with significance level of 0.05, two-sided test.

Study population:

Biopsy-confirmed LSIL patients, age more than 30 years-old, referred to either Srinagarind Hospital's, Khon Kaen Hospital's, or Roi Et Hospital's colposcopic clinics.

Inclusion criteria:

• Baseline HPV testing is positive.
• Be able to give their informed consent to this study.

Exclusion criteria:

• Having active cervical infection
• Having lesion of 2 mm-larger than probe
• Having lesion inside cervical os
• Having suspected cervical cancer lesion

Sample and sample size:

From previous studies, HPV clearance rate after cryotherapy at 12 months is 83.9%. (Elfgren, 2002) Spontaneous HPV clearance rate in young women at 24 months is 70%. (Moscicki, 1998) However, this HPV clearance rate in women older than 34 years-old at 12 months is only 53.6%. (Clavel, 2005) Using these numbers respectively as PE and PC putting in the formula below, we can calculate our sample size in each group. The sample size will be calculated to detect the 20-40% difference between the HPV clearance rates after 12 months, at significant level of 95% and power of 80% (two-sided test), using the approach of Lachin that was reviewed in the paper of Donner.(Donner, 1984)

Required sample size at different rate of clearance

P-control P-experimental Alpha level Power N Difference 95%CI 0.50 0.70 5% 80% 103 20 6.9-33.1 0.50 0.75 5% 80% 66 25 9-41 0.50 0.80 5% 80% 45 30 11.3-48.7 0.50 0.85 5% 80% 33 35 14-56 0.50 0.90 5% 80% 25 40 17.1-62.9

The sample size of at least 25 patients in each group will be chosen because of its precision and feasibility. Such sample size can detect 40% difference of HPV clearance rate between the two groups, at 95% significant level, with the power of 80%, 95%CI of 17.1-62.9, respectively.

Instruments:

After signing on the consent form, all eligible patients will be examined by the baseline standard procedures and PCR-HPV testing for 37 HPV types. Only positive HPV testing ones will be enrolled in the trial and then randomized to receive the cryotherapy or observation. The method of block randomization, with block size varies from 2 to 6, will be used to allocate treatments.

The allocation ratio is 1:1. The allocation sequence will be generated by computer, using STATA software version 10.0.

Based on the obtained schedule, the number of sealed envelopes, which are equal to the required blocks, will be prepared and labeled. Each envelope contains the corresponding sealed allocation cards that will allocate treatments to patients.

Colposcopy and cryotherapy instruments are available in our colposcopic clinic. However, we will reimburse for all CO2-gases tanks and materials used for Pap smears and HPV testing.

The people, who prepare the randomized scheme, will not involve in the trial. The allocation schedule will be concealed to the assessor (who measure the HPV testing) until the end of trial.

Data collection and measurement:

Because of the difference between two treatments, only the assessor (who measure the HPV testing) will be blinded from the treatments.

The specimens will be sent to the assessor without patient's name or HN that can be linked to the treatment received. They will be provided only the study ID number in which only the principle investigator can link it to the treatment received.

The main outcome is HPV clearance. It is measured by the gold-standard HPV testing. This will be performed at baseline and 12 months later.

Data analysis:

There were two main parts of analysis - describing selected characteristics of the study patients and analysis for answering the research questions. The first part, selected baseline characteristics of the patients in each treatment were compared i.e. age, sex, sexual experiences, underlying diseases, etc. Comparability of the distribution of those selected characteristics based on judgment rather than statistical significant tests. In this part, proportion was use for summarizing categorical data. For continuous data, the statistics include mean, standard deviation, minimum, maximum, and median.

For the second part, the analysis was based on the group in which the study patients were randomized (intention-to-treat basis). The different rate of clearance between the two arms of the trial and its 95% confidence interval will be calculated. This will be done at 12 months after the treatment. Z-test will be used for testing if such differences are different from zero. Multiple logistic regression will be used to control effects of any important confounding factors. Absolute risk reduction (ARR), relative risk reduction (RRR) and number needed to treat (NNT) will also be calculated.

The statistical analysis of this clinical trial will be performed based on intention-to-treat principle. All hypothesis tests are two-tailed at significant level of 0.05. Statistical package for all analysis is STATA version 10.0.